Comparative Pharmacology
Head-to-head clinical analysis: AFEDITAB CR versus PROCARDIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFEDITAB CR versus PROCARDIA.
AFEDITAB CR vs PROCARDIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
Initial dose: 10 mg orally 3 times daily; maintenance: 10-30 mg 3-4 times daily; maximum 180 mg/day. Extended-release (XL): 30-60 mg once daily; titrate up to 120 mg/day.
None Documented
None Documented
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
2-5 hours in healthy adults; up to 6-10 hours in cirrhotic patients or elderly; clinical context: requires extended-release formulations for once-daily dosing.
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
Renal (70-80% as metabolites, <1% unchanged); fecal (15-20% via bile); 0% unchanged in urine.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker